Vasculera Contraindications

General

CVI and its complications should be diagnosed and management monitored by a physician.

Hypersensitivity

VASCULERA is contraindicated for anyone having a hypersensitivity to any ingredient in the product. See “Description and Other Ingredients” for a full list of ingredients.

Patients with Cancer

Diosmin (up to 900 mg/day) has been administered to a small number of breast cancer patients who were experiencing lymphedema following surgical and nodal irradiation treatment with resultant reduction of arm edema but no effect on the cancer. Animal studies and more than 20 years of clinical use in Europe have not found any evidence of carcinogenicity or mutagenicity when the components of Vasculera are used as recommended. As a precaution, VASCULERA (diosmiplex) is not recommended for patients with a history of cancer since no specific studies have been performed in this population.

Pregnancy

Animal studies suggest that diosmin does not produce developmental abnormalities when consumed during pregnancy. A small number of pregnant women have consumed diosmin (up to 900 mg/day) in the third trimester and the first 4 weeks post-partum with no effect on the fetus or baby. Effects in infants of nursing mothers are uncertain for chronic dosing. Therefore, VASCULERA (diosmiplex) is not recommended in pregnant and lactating women. Women capable of becoming pregnant should consult with their physician before taking VASCULERA.

Vasculera Overview

Overall Rating
Medication Type
Other
Approval Date
Apr 02, 2012
DEA Schedule
Not Classified

Get The Daily Newsletter

Unsubscribe